Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF and Darbepoetin in Early Decompensated Cirrhosis
NCT07002827Recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Randomised, open-label trial of filgrastim and darbepoetin alfa in Liver cirrhosis (LC) (3 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Change in innate immunity between the groups at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
filgrastimdarbepoetin alfa
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07002827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002827.